header("Access-Control-Allow-Origin: *"); ?>
Thanks to its very high genome-editing efficiency, CRISPR-Cas9 technology could be a promising anti-cancer weapon. Clinical trials using CRISPR-Cas9 […]
The present invention relates to a method for preventing or treating a cancer disease by targeting the epigenetic factor Chromodomain on Y-like 2 […]
In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic […]
The present invention relates to the adoptive therapy using notably CAR-T cells. Herethe inventors used a lentiviral vector approach to silence RINF […]
The invention relates to a bispecific antibody targeting TfR1 and a soluble antigen. The inventors demonstrate that the unique mode of interaction of […]
Dose-limiting toxicity poses a major limitation to the clinical utility of targeted cancer therapies, often arising from target engagement in […]
Chemotherapy resistance is the major therapeutic barrier in acute myeloid leukemia (AML). To address this issue, the inventors generated a syngeneic […]
The present invention relates to lipid nanoparticle loaded with antitumoral agent andfunctionnalized to target immosuppressive cells. Inventors […]
Pediatric liver cancers (PLC) are rare tumors. In particular, hepatoblastomas are usually treated with cisplatin-based neoadjuvant chemotherapy […]
CAR macrophages (CAR-M) can phagocyte tumor cells expressing a target antigen. It is herein shown that the proprotein convertase furin is […]